Blog

PHARMA15 LIVE!

How Do Patients Feel About Hybrid
and Decentralized Clinical Trials?

What Are Must-Haves for
a Positive Patient Experience?

Patient advocates take center stage in this Pharma15 Live! overtime segment and share their thoughts on hybrid and decentralized clinical trials.

Moderated by BBK Worldwide Founding Principal Bonnie A. Brescia, this segment continues the conversation from a Patients as Partners Europe panel and answers questions asked by study sponsors in attendance.

Strategies to Help Improve Clinical Trial Diversity and Inclusion

From Engaging Locally to Removing Financial Obstacles

With health equity at the forefront of many conversations today, study sponsors are seeking ways to make clinical trial participation more inclusive.

At BBK Worldwide, we believe that clinical trials for investigational treatments should reflect the populations that could benefit from them, with the long-term goal of achieving better health interventions for those in greatest need. To help facilitate participation of underserved populations, we have outlined strategic guidance that study sponsors can leverage in their efforts.

We recently sat down with BBK’s Global Strategist Amanda Moody to discuss the company’s commitment to Parkinson’s disease clinical research, including ongoing innovation designed to foster a positive and meaningful patient journey. 

Can you briefly describe BBK’s experience with the Parkinson’s disease community?

We have a long-standing commitment to the Parkinson’s community, both in terms of supporting clinical research as well as individual patient and caregiver needs. 

Sharing in the commitment to advance research and knowledge for the Parkinson’s disease community, BBK Worldwide is proud to support the 2021 Parkinson’s Disease Therapeutics Webinar Series, hosted by The Michael J. Fox Foundation.

This free online series brings together Parkinson’s researchers, drug developers, and clinicians to discuss new findings and trending topics in Parkinson’s research and development.

BBK Worldwide Featured in Newly Published Innovations in Pharmaceutical Development™

Guide Provides In-Depth Profiles of World’s Most Disruptive Pharma Services Innovators

BBK Worldwide has been recognized as a top innovator in Innovations in Pharmaceutical Development™. This newly published guide highlights the companies and thought leaders at the forefront of innovation in the pharmaceutical development space. 

For part two of our Crystal Ball series, we asked a few more of our industry experts to comment on the clinical research landscape and to share their predictions for 2021.

Rob Laurens, Principal, RSG Services

Do you think a lot of the travel services rapidly deployed in response to COVID-19 will remain in effect? Will they become part of the standard offering?

Undoubtedly, many of the extraordinary support services deployed as a means to directly respond to the impact of the COVID-19 pandemic on clinical trial participant travel not only will remain available after the distribution and anticipated positive impact of vaccines, but also will be enhanced to serve the needs of a redefined approach and capabilities for clinical trial conduct by sponsors and CROs. 

As part of our Crystal Ball series, we asked BBK Worldwide President Matt Kibby to share his predictions for 2021, which include engaging  underrepresented populations in clinical research.

Matt Kibby, Principal, President

Is there a particular trend that you expect to have a significant impact on the industry in the coming year?

With COVID-19 dominating the headlines for much of 2020, one might expect that a key development for clinical R&D in 2021 will be the continued integration and expansion of services that support the hybridization / decentralization of clinical trials. Keeping trial participants – who tend to be older and at greater risk for complications from COVID-19 – away from clinical trial sites not only reduces the risk of SARS-COV-2 infection, but also offers the possibility of enrichment of the clinical trial experience; reduces the overall visit and expense burden for patients; and, moreover, reduces the trial burden on clinical trial site healthcare professionals.

What do doctors and nurses think about solutions designed to make clinical trials easier to conduct? Are they helpful? Do they alleviate burdens? And which ones do they prefer?

In this special Pharma15 Live! segment, BBK Worldwide industry experts Matt Kibby and Aaron Fleishman discuss recent Study Voices survey results that shed light on this topic. They examine doctor and nurse perspectives on services designed to provide support in conducting clinical trials — including services for virtual, hybrid, and decentralized clinical trials.

“We were looking at whether or not doctors and nurses at sites that were conducting clinical trials would appreciate different types of services that assist with their ability to conduct them."

-Matt Kibby, Principal, President, BBK Worldwide

Clinical Trial Innovation: More Important Now Than Ever

A new survey gives voice to the healthcare consumer in the wake of COVID-19 and highlights the importance of innovation in clinical trial patient enrollment and engagement.

DOWNLOAD NOW

New data provides clinical trial sponsors with the information they need to confidently embrace innovative solutions in response to COVID-19. The Study Voices 2020* survey reflects perspectives from patients, medical professionals, and members of the pharmaceutical industry. The findings reveal shifts in attitudes and behaviors since the onset of COVID-19 – insight that clinical trial sponsors can leverage for enrollment and engagement efforts, including for hybrid and virtual study models.

Earlier this week, Elizabeth Gargill went one-on-one with Outsourcing-Pharma, discussing findings from BBK's recent Study Voices survey that reveal shifts in healthcare consumer attitudes and behaviors since the onset of COVID-19. In this in-depth interview, Elizabeth discusses why clinical trial innovation is more important now than ever before and how clinical trial sponsors can leverage the survey findings to enhance their enrollment and engagement efforts.